Statements (41)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:brand |
gptkb:Fusilev
gptkb:Leucovorin_Calcium gptkb:Wellcovorin |
| gptkbp:clinical_trial |
studied for use in cancer therapy
studied for use in overdose situations |
| gptkbp:contraindication |
hypersensitivity to leucovorin
megaloblastic anemia due to vitamin B12 deficiency |
| gptkbp:dosage_form |
administered after methotrexate
varies based on indication |
| gptkbp:financial_products |
D B00866
|
| gptkbp:formulation |
available as injection
available as tablets |
| gptkbp:healthcare |
gptkb:battle
|
| https://www.w3.org/2000/01/rdf-schema#label |
Wellcovorin
|
| gptkbp:ingredients |
C20 H22 N8 O7 S
leucovorin calcium |
| gptkbp:interacts_with |
may interact with antiepileptic drugs
may interact with other folate antagonists |
| gptkbp:is_atype_of |
V03 A F01
|
| gptkbp:is_used_for |
treatment of colorectal cancer
treatment of methotrexate toxicity |
| gptkbp:manager |
oral
intravenous |
| gptkbp:manufacturer |
various pharmaceutical companies
|
| gptkbp:marketed_as |
gptkb:Wellcovorin
|
| gptkbp:pharmacokinetics |
excreted in urine
well absorbed orally reduces toxicity of methotrexate distributed widely in body tissues |
| gptkbp:related_to |
gptkb:methotrexate
folic acid |
| gptkbp:side_effect |
nausea
allergic reactions vomiting diarrhea |
| gptkbp:storage |
store at room temperature
protect from light |
| gptkbp:type_of |
58-05-9
|
| gptkbp:bfsParent |
gptkb:leucovorin
|
| gptkbp:bfsLayer |
5
|